Prevalence of cognitive impairment and cognitive improvement in patients with systemic lupus erythematosus during a 6-month follow-up study
12
item.page.dc.date.issued
2023-09-01
item.page.dc.type
item.page.dc.identifier.issn
09612033
item.page.dc.identifier.eissn
14770962
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85170349997
item.page.dc.identifier.pmid
37592859
item.page.oaire.citation.title
Lupus
item.page.oaire.citation.volume
32
item.page.oaire.citation.issue
10
item.page.oaire.citation.startPage
1199
item.page.oaire.citation.endPage
1210
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Lupus Vol.32 No.10 (2023) , 1199-1210
punsarn.item.page.citation
Koolvisoot A., Chumjang S. Prevalence of cognitive impairment and cognitive improvement in patients with systemic lupus erythematosus during a 6-month follow-up study. Lupus Vol.32 No.10 (2023) , 1199-1210. 1210. doi:10.1177/09612033231196215 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/90039
item.page.dc.title
Prevalence of cognitive impairment and cognitive improvement in patients with systemic lupus erythematosus during a 6-month follow-up study
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.other
item.page.dc.description.abstract
Objectives: The Montreal Cognitive Assessment (MoCA) is a simple and reliable screening tool for early detection for cognitive impairment in systemic lupus erythematosus (SLE). Most previous studies were cross-sectional with small samples. Research on long-term cognitive changes and reversibility is limited. This study aimed to establish the prevalence of cognitive impairment and changes in SLE patients after 6 months and the associated factors. Methods: A prospective study was conducted in 200 patients with SLE between April 2021 and March 2022. Demographic data, disease activity, and medications were recorded. MoCA was administered at baseline and 6 months; for Thais, scores 17–24 indicate mild cognitive impairment, while ≤16 signifies severe impairment. Multivariate analysis identified factors associated with cognitive impairment and improvement. Results: The patients’ median age was 44 years (range: 19–73), 96% were female, and 55% had < 12 years of education. The median disease duration was 11 years (range: 0–51.8), and 79% of patients had inactive disease. Cognitive impairment was found in 70% of patients (mild, 63%; severe, 7%). The most often affected domains were delayed recall (82%), abstraction (80.5%), language (76%) and visuospatial/executive function (70.5%), whereas orientation and naming were the least involved. Factors significantly associated with cognitive impairment were age > 40 years (OR, 3.71; 95% CI, 1.72–8.00), formal education < 12 years (OR, 3.11; 95% CI, 1.45–6.63), and prednisolone use (OR, 2.21; 95% CI, 1.08–4.51). Sixty-six (38.2%) of 173 patients completing the 6-month re-evaluation exhibited cognitive changes (52 [30.1%] improved; 14 [8.1%] deteriorated). Except for delayed recall, all commonly affected domains showed significant improvement. Disease activity, prednisolone, antimalarials, or immunosuppressant use did not predict cognitive improvement. Conclusions: Mild cognitive impairment is prevalent among patients with SLE. Due to the possibility of reversibility, early recognition and additional research to identify relevant factors are required.